[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2195169T3 - Vacunas contra calmidias y composiciones inmunogenicas que contienen un antigeno de membrana externa y metodos para su preparacion. - Google Patents

Vacunas contra calmidias y composiciones inmunogenicas que contienen un antigeno de membrana externa y metodos para su preparacion.

Info

Publication number
ES2195169T3
ES2195169T3 ES97939910T ES97939910T ES2195169T3 ES 2195169 T3 ES2195169 T3 ES 2195169T3 ES 97939910 T ES97939910 T ES 97939910T ES 97939910 T ES97939910 T ES 97939910T ES 2195169 T3 ES2195169 T3 ES 2195169T3
Authority
ES
Spain
Prior art keywords
chlamydia
external membrane
calmidies
membrane antigen
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97939910T
Other languages
English (en)
Inventor
Andrew D Murdin
Brian J Underdown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Sanofi Pasteur SA
Original Assignee
Aventis Pasteur Ltd
Aventis Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur Ltd, Aventis Pasteur SA filed Critical Aventis Pasteur Ltd
Application granted granted Critical
Publication of ES2195169T3 publication Critical patent/ES2195169T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

ESTA INVENCION SE REFIERE A UNAS COMPOSICIONES INMUNOLOGICAS QUE COMPRENDEN UN EXTRACTO ANTIGENO DE MEMBRANA DE UNA CEPA DE CHLAMYDIA Y SON EFICACES EN LA PROTECCION CONTRA LA ENFERMEDAD PROVOCADA POR LA INFECCION DE CHLAMYDIA. LAS COMPOSICIONES INMUNOLOGICAS PUEDEN COMPRENDER LA PROTEINA DE LA MEMBRANA EXTERIOR PRINCIPAL (MOMP) DE CHLAMYDIA, QUE PUEDE TENER UNA FORMA ISOOLIGOMERICA O EN COMPLEJO CON, POR LO MENOS, OTRO ANTIGENO DE CHLAMYDIA. LA COMPOSICION INMUNOLOGICA PUEDE INCLUIR UN COMPLEJO INMUNOESTIMULANTE (ISCOM) Y SE PUEDE INCORPORAR EL ANTIGENO DE MEMBRANA EXTERIOR. DICHAS COMPOSICIONES INMUNOLOGICAS TIENEN UNA UTILIDAD COMO VACUNAS ANTI - CHLAMYDIAE Y PARA CIERTAS APLICACIONES DE DIAGNOSTICO.
ES97939910T 1996-09-12 1997-09-11 Vacunas contra calmidias y composiciones inmunogenicas que contienen un antigeno de membrana externa y metodos para su preparacion. Expired - Lifetime ES2195169T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/713,236 US6464979B1 (en) 1996-09-12 1996-09-12 Chlamydial vaccines and methods of preparation thereof

Publications (1)

Publication Number Publication Date
ES2195169T3 true ES2195169T3 (es) 2003-12-01

Family

ID=24865335

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97939910T Expired - Lifetime ES2195169T3 (es) 1996-09-12 1997-09-11 Vacunas contra calmidias y composiciones inmunogenicas que contienen un antigeno de membrana externa y metodos para su preparacion.

Country Status (10)

Country Link
US (2) US6464979B1 (es)
EP (1) EP0957935B1 (es)
AT (1) ATE234630T1 (es)
AU (1) AU4195897A (es)
CA (1) CA2280037A1 (es)
DE (1) DE69720056T2 (es)
DK (1) DK0957935T3 (es)
ES (1) ES2195169T3 (es)
PT (1) PT957935E (es)
WO (1) WO1998010789A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258532B1 (en) 1997-08-14 2001-07-10 Vanderbilt University Methods for in vitro susceptibility testing of chlamydia
US6710033B1 (en) 1996-08-14 2004-03-23 Vanderbilt University Methods and treatment of multiple sclerosis
US6890526B2 (en) 1997-05-06 2005-05-10 Vanderbilt University Methods and reagents for the treatment of multiple sclerosis
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
NZ512730A (en) 1998-12-04 2003-12-19 Univ Manitoba A immunization procedure against chlamydia infection using an attenuated bacteria comprsing a plasmid with a major outer membrane protein (MOMP) from chlamydial
US6555115B1 (en) 1998-12-08 2003-04-29 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
TR200102500T2 (tr) * 1998-12-08 2002-03-21 Corixa Corporation Chlamydia enfeksiyonunu tedavi etmek i‡in bileçikler.
US6448234B1 (en) 1998-12-08 2002-09-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6432916B1 (en) 1998-12-08 2002-08-13 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US6447779B1 (en) 1998-12-08 2002-09-10 Corixa Corporation Compounds for the diagnosis of Chlamydial infection
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
AU3760400A (en) * 1999-03-19 2000-10-09 Vanderbilt University Methods and reagents for the diagnosis and treatment of multiple sclerosis
DE19939246A1 (de) * 1999-08-19 2001-02-22 Phasys Gmbh M Rückfaltung von Membranproteinen
NZ520200A (en) * 1999-12-22 2004-04-30 Aventis Pasteur Polynucleotides encoding the Clamydia pneumoniae polypeptides omp P6 precursor gene product
US20010048927A1 (en) 2000-02-01 2001-12-06 Richard Stephens Porin B (PorB) as a therapeutic target for prevention and treatment of infection by chlamydia
GB0003217D0 (en) * 2000-02-11 2000-04-05 Yaba Ltd Invention
US6919187B2 (en) 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
DE60133190T2 (de) 2000-04-21 2009-04-02 CORIXA CORP., Wilmington Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
AUPQ954000A0 (en) * 2000-08-18 2000-09-14 Queensland University Of Technology Novel diagnostic agents and uses therefor
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
US7105171B2 (en) 2002-03-07 2006-09-12 The Regents Of The University Of California Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia
TWI341836B (en) * 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
ES2325243B1 (es) * 2008-02-27 2011-05-04 Universidad De Granada Antigeno recombinante.
AU2010207828B2 (en) 2009-01-29 2016-07-14 British Columbia Cancer Agency Branch Compositions comprising Chlamydia antigens
US8735543B2 (en) 2010-05-28 2014-05-27 Spixia Biotechnology Ab Chimeric MOMP antigen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427782A (en) 1981-03-03 1984-01-24 Caldwell Harlan D Isolation of principal outer membrane protein and antigen of Chlamydia trachomatis
GB8919819D0 (en) * 1989-09-01 1989-10-18 Coopers Animal Health Complexes having adjuvant activity

Also Published As

Publication number Publication date
DK0957935T3 (da) 2003-06-23
CA2280037A1 (en) 1998-03-19
ATE234630T1 (de) 2003-04-15
US6464979B1 (en) 2002-10-15
DE69720056T2 (de) 2003-10-30
WO1998010789A1 (en) 1998-03-19
PT957935E (pt) 2003-08-29
AU4195897A (en) 1998-04-02
EP0957935B1 (en) 2003-03-19
EP0957935A1 (en) 1999-11-24
US6635746B1 (en) 2003-10-21
DE69720056D1 (de) 2003-04-24

Similar Documents

Publication Publication Date Title
ES2195169T3 (es) Vacunas contra calmidias y composiciones inmunogenicas que contienen un antigeno de membrana externa y metodos para su preparacion.
EA200801307A1 (ru) Вакцинные композиции, содержащие сапониновый адъювант
PT1284998E (pt) Eptideos imunogenicos sinteticos mas nao-amiloidogenicos homologos a beta-amiloides, destinados a induzir uma reaccao imunitaria contra os beta-amiloides e os depositos amiloides
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
SE0202110D0 (sv) Iscom preparation and use thereof
CO5700790A2 (es) Composiciones de vacuna que comprenden una interleucina 18 y sistema de adyuvante de saponina
AR047728A1 (es) Adyuvante antimicrobiano y uso de agentes antimicrobianos como adyuvante de vacunas
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
BR0109289A (pt) Uso de extratos vegetais e açúcares para proteger tecido queratinoso
UY27843A1 (es) Composicion de vacuna
MA29406B1 (fr) Vaccin toxoide alpha de c. perfringens
BR0007936A (pt) Composto, formulação adjuvante imunológica, formulação de vacina, e, processo para estimular uma resposta imune a um antìgeno
BRPI0510430A (pt) composições e métodos para vacinação mucosal
BR0212556A (pt) interleucina-12 como um adjuvante de vacina veterinária
CO5611162A2 (es) Metodos para prevenir enfermedades reproductivas en el ganado vacuno
AR023535A1 (es) Nuevas composiciones.
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
UA107177C2 (uk) Імуногенна композиція цвс2 та спосіб приготування такої композиції
PE117199A1 (es) Formulaciones parasiticidas
BR0014666A (pt) Vacina
BR9814958B1 (pt) Proteína de cimento de tecido, composição farmacêutica, uso da proteína de cimento de tecido, vacina, processos para produção de vacina, para ligação de tecido de animal e para preparação de uma protéina de cimento de tecido
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
BR0111785A (pt) Composições e métodos para tratamento de candidìase